NRx Pharmaceuticals, Inc. Q2 FY2025 earnings call

• Vital advances across programs with 3 drug approval applications in progress and Hope Therapeutics clinics. - Reduced quarterly operating loss by approximately 50% year-over-year and filed over 80,000 pages of regulatory data last quarter. - Strengthened balance sheet with long-term health care specialist investors, including a 1-year lockup agreement and no dilutive features. - NRX-100: Following 2 parallel approval processes, preservative-free IV ketamine, FDA broadened Fast Track designation, filed ANDA in June with FDA addressing discrepancies. - NRX-101: Filed module 3 with FDA under breakthrough therapy designation, aims for rolling review and priority review, addresses unmet need in bipolar depression with akathisia. - Hope Therapeutics: Finalizing purchase of first clinics, awaiting acquisition financing, aiming to build premier interventional psychiatry clinic network. - FDA granted PDUFA fee waiver, saving $4.3 million.

No detailed breakdown of revenue contribution by product segments provided. Focus is on drug development and Hope Therapeutics clinics with key advances in programs but no specific absolute revenue figures per segment.

• Current cash position supports operations well into 2026 and provides capital to reach regulatory milestones. - Singular focus on advancing primary drug development initiatives and planned clinic acquisitions to build long-term value.

• Uncertainty in FDA response timelines for the citizen petition on benzethonium chloride. - Difficulty for existing suppliers to adjust to preservative-free formulations for ketamine. - Regulatory uncertainties and potential delays in drug approval processes.

Q: Why is the pathway for NRX-101 accelerated approval?

A: Secondary endpoints of reduction in akathisia and suicidality are intermediate endpoints, seeking accelerated approval for unmet medical need where there's a critical risk of self-harm with no current treatment options.

Q: Is it clear the CNPV can be sold the way the other vouchers were?

A: The agency has been clear that CNPV's are not to be sold, and our sole objective is to get the drug to patients as a life-saving treatment for a critical unmet medical need.

Q: Any expense guidance for R&D and G&A?

A: Loss from operations reduced by more than 3.3 million or 47% compared to prior year, driven by internal budgeting and cost-saving measures, with loss from operations being a cleaner view of financial picture.

Q: What's the acquisition pipeline for clinics?

A: Aim to acquire best-in-breed interventional psychiatry clinics, shift to building clinics from the ground up, with a goal of a national network in place in 5 years similar to DaVita and Fresenius in dialysis.

Q: When may expect FDA response on citizen petition for benzethonium chloride?

A: FDA to respond to citizen's petition within 6 months of filing, potential revenue uplift if FDA mandates preservative-free formulation, but existing suppliers may not adjust easily.

Q: How will FDA weigh real-world data for NRX-100?

A: Real-world data from nearly 180,000 patients should motivate FDA to strengthen the case for approval, as it's a unique circumstance with a large number of patients having received the drug for the purpose.

Q: Synergy between NRX-101 and TMS?

A: Provocative study shows potential enhancement of TMS effect by NRX-101, may seek label expansion for combination to accelerate adoption.

Q: Commercial strategy for NRX-100 and 101?

A: Focused commercial forces, likely launch with small teams targeting specific clinics and psychiatrists, similar to past successful launches at MedImmune and Lev Pharma.